

International Interdisciplinary Congress on Renewable Energies, Industrial Maintenance, Mechatronics and Informatics Booklets



RENIECYT - LATINDEX - Research Gate - DULCINEA - CLASE - Sudoc - HISPANA - SHERPA UNIVERSIA - Google Scholar DOI - REDIB - Mendeley - DIALNET - ROAD - ORCID

Title: Pro-Inflammatory cytokines: Leptin and visfatin associated to obesity in young university students

Authors: DÍAZ-BURKE, Yolanda, GONZÁLEZ-SANDOVAL, Claudia Elena, UVALLE-NAVARRO, Rosario Lizette and MEDEROS-TORRES, Claudia Verónica

Editorial label ECORFAN: 607-8695 BCIERMMI Control Number: 2021-01 BCIERMMI Classification (2021): 271021-0001

Pages: 06 RNA: 03-2010-032610115700-14

ECORFAN-México, S.C. **Holdings** 143 – 50 Itzopan Street Mexico Colombia Guatemala La Florida, Ecatepec Municipality Bolivia Cameroon **Democratic** Mexico State, 55120 Zipcode www.ecorfan.org Phone: +52 | 55 6|59 2296 Spain Republic El Salvador Skype: ecorfan-mexico.s.c. Ecuador Taiwan of Congo E-mail: contacto@ecorfan.org Facebook: ECORFAN-México S. C. Peru **Paraguay** Nicaragua Twitter: @EcorfanC

Introduction

Obesity has been associated with the development of important degenerative diseases such as hypertension, metabolic syndrome, diabetes mellitus (DM), cardiovascular disease (CVD), cancer, among others. And is also described that the disease severity of infections illnesses such as coronavirus, influenza, parainfluenza, and rhinovirus in increased. Besides, in 2009 was recognized as a risk factor during the pandemic of influenza H1N1 Currently there are several studies which suggest that some adipocytokines as leptin, resistin, plasminogen activator inhibitor-1 (PAI-1), adiponectin, visfatina among others have mediators affects in cardiovascular system.

Some authors had shown plasmatic levels of leptin seem to be one of the best biological markers of obesity, and hyperleptinemia is closely related with several metabolic risk factors on insulin resistance in DM Some studies reveals that visfatin have mimetic affects with insulin in muscle stimulation and in glucose transport in adipocyte, also inhibit glucose production in liver.

Methodology

Cross-sectional study.

• The present study was carried out in the facilities of the Centro Universitario de Ciencias Exactas e Ingenierías of the Universidad de Guadalajara.

• We recruit 171 young students (57.6 % female, 42.4% male) with the following characteristics: age between 18- 25 years old, fasting of 8 to 10 hours to take the blood sample.

Results

• The results shows that BMI is higher in male and triglycerides also. On the other hand, leptin levels and total cholesterol are higher in women. The group with hyperleptinemia has higher values of BMI, total cholesterol, triglycerides, LDL and visfatina comparing with the group with normal leptin levels.

• We observed that hyperleptinemia is a risk factor for the development of obesity with OR 5.86 (p=0.01), in the other hand, visfatina acts as a protector factor with OR 0.2901 (0.02).

Conclusions

Therapeutic intervention in early stages previous the beginning of the metabolic complications could have a favorable cost-benefit. However, the incorporation of markers such as the size of the particle of LDL, insulin resistance index, adipocytokines pro inflammatory as leptin and visfatin could improve the current predictive capacity.

References

- Choe, S. S., Huh, J. Y., Hwang, I. J., Kim, J. I., & Kim, J. B. (2016). Adipose Tissue Remodeling: Its Role in Energy Metabolism and Metabolic Disorders. Frontiers in endocrinology, 7, 30. https://doi.org/10.3389/fendo.2016.00030
- Drucker D. J. (2021). Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning. Cell metabolism, 33(3), 479–498. https://doi.org/10.1016/j.cmet.2021.01.016
- Hugo, E. R., y Ben-Jonathan, N. (2016). . Endocrine Disruptors, Adipokines and he Metabolic Syndrome. Adipokines, 228.
- Kwok, S., Adam, S., Ho, J. H., Iqbal, Z., Turkington, P., Razvi, S., Le Roux, C. W., Soran, H., & Syed, A. A. (2020). Obesity: A critical risk factor in the COVID-19 pandemic. Clinical obesity, 10(6), e12403. https://doi.org/10.1111/cob.12403



© ECORFAN-Mexico, S.C.

No part of this document covered by the Federal Copyright Law may be reproduced, transmitted or used in any form or medium, whether graphic, electronic or mechanical, including but not limited to the following: Citations in articles and comments Bibliographical, compilation of radio or electronic journalistic data. For the effects of articles 13, 162,163 fraction I, 164 fraction I, 168, 169,209 fraction III and other relative of the Federal Law of Copyright. Violations: Be forced to prosecute under Mexican copyright law. The use of general descriptive names, registered names, trademarks, in this publication do not imply, uniformly in the absence of a specific statement, that such names are exempt from the relevant protector in laws and regulations of Mexico and therefore free for General use of the international scientific community. BCIERMMI is part of the media of ECORFAN-Mexico, S.C., E: 94-443.F: 008- (www.ecorfan.org/booklets)